Advertisement

Topics

Bauml Discusses State of Immunotherapy Biomarkers in NSCLC

10:34 EDT 10 Jul 2018 | OncLive

Joshua Bauml, MD, discusses the limitations of PD-L1 and tumor mutational burden as immunotherapy biomarkers in non–small cell lung cancer and emerging biomarkers showing promise in the field.

Original Article: Bauml Discusses State of Immunotherapy Biomarkers in NSCLC

NEXT ARTICLE

More From BioPortfolio on "Bauml Discusses State of Immunotherapy Biomarkers in NSCLC"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...